Financial Comparison: Varex Imaging (VREX) versus Myriad Genetics (MYGN)
Varex Imaging (NASDAQ: VREX) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.
Institutional & Insider Ownership
91.8% of Varex Imaging shares are owned by institutional investors. 6.2% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Varex Imaging and Myriad Genetics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Varex Imaging||$654.50 million||1.84||$115.80 million||N/A||N/A|
|Myriad Genetics||$771.40 million||2.87||$97.70 million||$0.32||101.07|
Varex Imaging has higher revenue, but lower earnings than Myriad Genetics.
This table compares Varex Imaging and Myriad Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for Varex Imaging and Myriad Genetics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Varex Imaging presently has a consensus target price of $33.50, indicating a potential upside of 4.62%. Myriad Genetics has a consensus target price of $20.38, indicating a potential downside of 37.00%. Given Varex Imaging’s stronger consensus rating and higher possible upside, research analysts plainly believe Varex Imaging is more favorable than Myriad Genetics.
Myriad Genetics beats Varex Imaging on 7 of the 11 factors compared between the two stocks.
About Varex Imaging
Varex Imaging Corporation is a supplier of medical X-ray tubes and image processing solutions. The Company’s segments include Medical and Industrial. The X-ray imaging system manufacturers use the Company’s components for medical imaging, cargo screening and border security, to detect, diagnose and protect. The Medical business segment designs, manufactures, sells and services X-ray imaging components for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, special procedures, computed tomography, radiation therapy and computer-aided detection. The Industrial business segment designs, manufactures, sells and services products for use in security and industrial inspection applications, such as cargo screening at ports and borders and non-destructive examination in a range of applications.
About Myriad Genetics
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
Receive News & Stock Ratings for Varex Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Varex Imaging and related stocks with our FREE daily email newsletter.